NanoViricides (NYSE:NNVC) Upgraded to “Strong-Buy” at Noble Financial

Noble Financial upgraded shares of NanoViricides (NYSE:NNVC) to a strong-buy rating in a report issued on Monday morning,Zacks.com reports.

NanoViricides Stock Down 0.5%

Shares of NNVC traded down $0.01 during mid-day trading on Monday, reaching $1.49. 198,941 shares of the company’s stock were exchanged, compared to its average volume of 579,847. NanoViricides has a 52-week low of $0.85 and a 52-week high of $2.23. The company has a 50-day simple moving average of $1.45 and a two-hundred day simple moving average of $1.21. The company has a market cap of $34.29 million, a price-to-earnings ratio of -2.09 and a beta of 1.67.

Institutional Investors Weigh In On NanoViricides

Several hedge funds have recently modified their holdings of NNVC. Susquehanna International Group LLP raised its position in shares of NanoViricides by 37.4% in the third quarter. Susquehanna International Group LLP now owns 52,217 shares of the company’s stock valued at $75,000 after buying an additional 14,217 shares during the last quarter. State Street Corp raised its holdings in NanoViricides by 29.4% in the 4th quarter. State Street Corp now owns 54,206 shares of the company’s stock valued at $61,000 after acquiring an additional 12,300 shares during the last quarter. Miller Financial Services LLC purchased a new position in shares of NanoViricides during the 4th quarter worth $81,000. Jane Street Group LLC acquired a new stake in shares of NanoViricides during the fourth quarter worth $140,000. Finally, Geode Capital Management LLC boosted its holdings in shares of NanoViricides by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 174,371 shares of the company’s stock worth $197,000 after purchasing an additional 14,944 shares during the last quarter. 10.30% of the stock is owned by institutional investors and hedge funds.

NanoViricides Company Profile

NanoViricides, Inc is a clinical-stage biotechnology company focused on the development of novel antiviral therapies using its proprietary nanomicelle technology. The company designs polymeric, virus-targeted nanoviricides that seek to neutralize viral pathogens by binding to specific viral surface proteins and destroying their structural integrity. NanoViricides’ platform is intended to offer broad-spectrum activity against a range of enveloped viruses, positioning it as a potential solution for both existing and emerging viral threats.

The company’s pipeline includes preclinical and early clinical candidates targeting seasonal and pandemic influenza strains, as well as investigational programs for coronaviruses, hepatitis, dengue, HIV and other viruses.